Desjardins Global Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Desjardins Global Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-831	Closed	-$96.1K	–	704
2023 Q3	$96.1K	Buy	+831	New	+$89.3K	0.01%	479
2023 Q2	–	Sell	-2,124	Closed	-$232K	–	656
2023 Q1	$232K	Sell	2,124 -489	-19%	-$54.1K	0.03%	388
2022 Q4	$297K	Buy	2,613 +185	+8%	+$15.4K	0.05%	298
2022 Q3	$150K	Hold	2,428	–	–	0.02%	367
2022 Q2	$193K	Buy	+2,428	New	+$230K	0.03%	350

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Desjardins Global Asset Management's HZNP Position: Q4 2023 in Review

Desjardins Global Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 831 shares — an estimated $96.1K sold.

Desjardins Global Asset Management first reported a position in HZNP in Q2 2022 and held it in 5 quarters. The position peaked at $297K in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Desjardins Global Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Desjardins Global Asset Management sold 831 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $96.1K.
Desjardins Global Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 5 quarters.
Desjardins Global Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $297K in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.